-

Modernized Integrated Data Technology Platform, Artemetrx, Now Available to Proactively Manage Drug Costs and Clinical Outcomes

Innovative health tech transforms integrated pharmacy and medical data into actionable intelligence

DALLAS--(BUSINESS WIRE)--Modernized health tech platform, Artemetrx, is now available for the unprecedented transformation of integrated data into meaningful strategies and proactive drug cost management for employers and managed care organizations (MCO).

Artemetrx is a proprietary platform developed by Pharmaceutical Strategies Group (PSG), an EPIC company. It has been revolutionized to deliver unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes.

“We’re rolling out this groundbreaking technological advancement, so plans immediately and continuously understand their most significant drug management opportunities and effortlessly manage against the overwhelming current of change in the pharmacy landscape,” said Michael Lonergan, RPh, President of PSG. “By leveraging the value of integrated data, PSG identifies $4.8 billion annually in actionable drug cost savings.”

Plans experienced an 18 percent increase in members utilizing at least one specialty drug (2017 to 2019), according to PSG’s 2020 State of Specialty Spend and Trend Report. The need to stay ahead of the curve in managing drug costs and care has never been so crucial.

Artemetrx empowers health plans and employers to do more and do it faster, with innovative features like:

  • Total cost of care analysis to support smart clinical strategies and stronger patient outcomes
  • Clinical rules engine powered by over 1,000 unique parameters to identify emerging fraud schemes and outlier prescribers/pharmacies before they become a million-dollar problem
  • Integrated pharmacy and medical data for greater transparency and significant insights into medical drug management

“Some of the most sophisticated health plans in the country are already using the completely modernized Artemetrx platform,” said Libby Johnson, Senior Vice President of Client Success, Clinical, and Analytics. “The MCO space is more competitive than ever. This health tech platform is setting plans apart and moving the needle for them with integrated insights.”

Discover how Artemetrx transforms billions of claims records into actionable drug management insights for over 22 million integrated lives.

https://www.psgconsults.com/discoverartemetrx

About PSG

Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG’s innovative drug management solutions, including the proprietary data and analytics platform, Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year.

Contacts

Samantha Rideout
Marketing Director, PSG
srideout@psgconsults.com
469.974.6152

Pharmaceutical Strategies Group


Release Summary
Innovative health tech transforms integrated pharmacy and medical data into actionable intel to proactively manage drug costs and clinical outcomes
Release Versions

Contacts

Samantha Rideout
Marketing Director, PSG
srideout@psgconsults.com
469.974.6152

Social Media Profiles
More News From Pharmaceutical Strategies Group

PSG Announces Results of Highly Comprehensive Pharmacy Benefit Manager Survey

DALLAS--(BUSINESS WIRE)--Pharmaceutical Strategies Group (PSG), an EPIC company, has released its 25th annual 2022 Pharmacy Benefit Manager Customer Satisfaction Report. This extensive report represents the most comprehensive satisfaction research survey in the pharmacy benefit manager (PBM) space, providing unparalleled data and insights. PBM satisfaction rankings in 2022 There was a notable downturn in overall satisfaction levels, as well as in some core measures of general satisfaction such...

PSG Announces New Features Designed to Support Biosimilar Strategy

DALLAS & SAN FRANCISCO--(BUSINESS WIRE)--Pharmaceutical Strategies Group (PSG), an EPIC company, announced an enhancement of its data and analytics platform, Artemetrx®, which will significantly enhance clients’ ability to track and report on the adoption of biosimilar medications. Artemetrx is the leading integrated pharmacy and medical claims platform and is utilized by health plans, pharmacy benefit managers, and employers for drug cost management. While biosimilars have been available in th...

Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group

DALLAS--(BUSINESS WIRE)--The Artemetrx Specialty Spend and Trend Report, by PSG, shows biosimilar adoption, but double-digit specialty drug trend persists....
Back to Newsroom